AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer

RecruitingNAAges 18 Years - 75 YearsAllZhejiang University
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to compare the long-term outcomes of Laparoscopic Ileocecal-Sparing Right Hemicolectomy(LISH) compared to traditional laparoscopic right hemicolectomy(TRH) in the treatment of hepatic flexure colon cancer and proximal transverse colon cancer.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age between 18-75 years old 2. ASA classification ≤III 3. Colon adenocarcinoma confirmed by endoscopy and pathological biopsy 4. Enhanced abdominal CT indicating the primary lesion is located in the hepatic flexure of the colon or proximal transverse colon (proximal 1/3 of the transverse colon) 5. Preoperative clinical staging: TanyNanyM0 6. Patients able to understand the study protocol, willing to participate in the research, and providing written informed consent Exclusion Criteria: 1. Preoperative examination indicates synchronous multiple primary colorectal cancers or other diseases requiring bowel segment resection 2. Preoperative imaging or intraoperative exploration reveals: 1) tumor involving surrounding organs requiring combined organ resection; 2) presence of distant metastasis; 3) inability to perform R0 resection; 4) fused and fixed lymph nodes at the root of the ileocolic vessels 3. Additional radical surgery following Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD) procedures 4. History of any other malignant tumor within the last 5 years or familial adenomatous polyposis, except for cured in situ cervical cancer, basal cell carcinoma, papillary thyroid carcinoma, or skin squamous cell carcinoma 5. Presence of bowel obstruction, bowel perforation, or intestinal bleeding requiring emergency surgery 6. Patients unsuitable for or unable to tolerate laparoscopic surgery 7. Pregnant or lactating women 8. Patients with a history of psychiatric disorders 9. Patients who have received neoadjuvant therapy prior to surgery 10. Patients deemed unsuitable for the study by MDT discussion 11. Patients unable to understand the study's conditions and objectives, and refusing to sign informed consent.
💊

What it tests

  • LISH (Laparoscopic Ileocecal-Sparing Right Hemicolectomy)
  • TRH(Traditional Laparoscopic Right Hemicolectomy)
📍

Where

29 sites
the First Affiliated Hospital of Bengbu Medical Collage
Bengbu, China
Beijing Cancer Hospital
Beijing, China
Peking Union Medical College Hospital
Beijing, China
Cancer Hospital Academy of medicine Scenice
Beijing, China
the First Affiliated Hospital of Chongqing Medical Collage
Chongqing, China
Fujian Cancer Hospital
Fuzhou, China
Fujian Hospital Medical Union University
Fuzhou, China
The First Affiliated Hospital of Xiamen University
Xiamen, China

…and 21 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy